UltraClot® Technology

The UltraClot® formulation is a patented and FDA approved hemostatic technology that provides a platform for application specific products designed to control severe hemorrhage under the most adverse conditions.

UltraClot®'s unique formulation increases the absorption rate and capacity of the hemostatic gauze through its layers, wicking excess blood from the wound site while accelerating clot formation. Its efficacy is proven by the results of the Comparative Performance Study contained herein and the lives it has saved on the battlefield. Currently, UltraClot® products are in use by U.S. Special Forces; U.S. Dept. of State; Afghan, Iraq, and Kurdish Armed Forces; and an NGO in Africa.

BallistiClot® is the catheter injected slurry form of the UltraClot® formulation which controls severe hemorrhage in narrow entry / exit wounds even with indirect wound tracks where visualization of the wound source is impossible.

UltraClot® OTC products control bleeding in people with clotting issues, including those taking blood thinners.

UltraClot® has been proven safe. The primary active ingredient is beneficiated hectorite clay. “Hectorite is a clay mineral similar in structure to MMT (montmorillonite) but with more negative charges on its surface. It is also hydrophilic swelling clay composed of silicate sheets which delaminate in water to provide an open three dimensional structure.”¹ Unlike other clay based hemostatic agents, this open three dimensional structure eliminates ANY possibility of occlusion or thrombosis. It is even used as a drug delivery vehicle for controlled release of therapeutic agents injected into highly vascular tumors.